February 18, 1997Circulation
Acute Profound Thrombocytopenia After c7E3 Fab (Abciximab) Therapy
Why the study?
Does abciximab cause acute profound thrombocytopenia in patients undergoing percutaneous coronary revascularization?
Population
Patients at Duke University Medical Center who underwent percutaneous coronary revascularization and…
Design
Cohort
Follow-up
up to 2 weeks
Authors
Discussion
Loading...
Member takes
Implication
Abciximab may cause acute profound thrombocytopenia; leaves open optimal monitoring protocols pending larger prospective data.
Structured PICO
Does abciximab cause acute profound thrombocytopenia in patients undergoing percutaneous coronary revascularization?
P
Population
Patients at Duke University Medical Center who underwent percutaneous coronary revascularization and received their first exposure to c7E3 Fab (abciximab) between November 1991 and July 1996
I
Intervention
c7E3 Fab (abciximab) bolus
O
Outcome
Development of acute profound thrombocytopenia, defined as a platelet count < 20 x 10(9)/L occurring within 24 hours of initial treatmentsafety
Abciximab administration during percutaneous coronary revascularization can cause unpredictable acute profound thrombocytopenia, highlighting the need for platelet count monitoring 2 to 4 hours post-bolus.
Cite This Study
Berkowitz et al. (1997) studied this question.